[go: up one dir, main page]

WO2003016905A3 - Determination of t-cell/mayor histocompatibility complex (mhc) reactivity - Google Patents

Determination of t-cell/mayor histocompatibility complex (mhc) reactivity Download PDF

Info

Publication number
WO2003016905A3
WO2003016905A3 PCT/GB2002/003753 GB0203753W WO03016905A3 WO 2003016905 A3 WO2003016905 A3 WO 2003016905A3 GB 0203753 W GB0203753 W GB 0203753W WO 03016905 A3 WO03016905 A3 WO 03016905A3
Authority
WO
WIPO (PCT)
Prior art keywords
mhc
cell
histocompatibility complex
reactivity
determination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/003753
Other languages
French (fr)
Other versions
WO2003016905A2 (en
Inventor
Bent Karsten Jakobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidex Ltd filed Critical Avidex Ltd
Priority to AU2002319547A priority Critical patent/AU2002319547A1/en
Publication of WO2003016905A2 publication Critical patent/WO2003016905A2/en
Publication of WO2003016905A3 publication Critical patent/WO2003016905A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a method for determining whether a T cell reacts with a predetermined Major Histocompatibility Complex (MHC) type. In the method, a sample comprising said T cell is brought into contat with a plurality of molecules of said MHC type, each MHC molecule being complexed with a peptide antigen whose contribution to a T cell receptor binding the MHC-peptide antigen complex is minimised. Whether said plurality of MHC molecules causes activation of the T cell is then determined. The method can assess allo-specific T cell activity, and may be used in matching transplant and donor patients, as well as in monitoring alloreactive responses following a transplant operation.
PCT/GB2002/003753 2001-08-16 2002-08-15 Determination of t-cell/mayor histocompatibility complex (mhc) reactivity Ceased WO2003016905A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002319547A AU2002319547A1 (en) 2001-08-16 2002-08-15 Determination of t-cell/mayor histocompatibility complex (mhc) reactivity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120042.7 2001-08-16
GB0120042A GB0120042D0 (en) 2001-08-16 2001-08-16 Methods

Publications (2)

Publication Number Publication Date
WO2003016905A2 WO2003016905A2 (en) 2003-02-27
WO2003016905A3 true WO2003016905A3 (en) 2003-10-30

Family

ID=9920550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003753 Ceased WO2003016905A2 (en) 2001-08-16 2002-08-15 Determination of t-cell/mayor histocompatibility complex (mhc) reactivity

Country Status (3)

Country Link
AU (1) AU2002319547A1 (en)
GB (1) GB0120042D0 (en)
WO (1) WO2003016905A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US20090061478A1 (en) 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
US20110038881A1 (en) * 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (en) 2008-02-28 2019-09-09 Dako Denmark As MHC multimers for Borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
WO2021087579A1 (en) * 2019-11-08 2021-05-14 The University Of Sydney Compositions for detecting alloreactive t cells
WO2024227447A1 (en) * 2023-05-03 2024-11-07 Immunoracle Inc. Compositions and methods of analyzing a sample for antigen-specific immune cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALTMAN J ET AL: "Phenotypic analysis of antigen-specific T lymphocytes", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 94 - 96, XP002135711, ISSN: 0036-8075 *
CLAAS FRANS H J: "Predictive parameters for in vivo alloreactivity.", TRANSPLANT IMMUNOLOGY. ENGLAND AUG 2002, vol. 10, no. 2-3, August 2002 (2002-08-01), pages 137 - 142, XP002249197, ISSN: 0966-3274 *
FALK K ET AL: "ALLELE-SPECIFIC PEPTIDE LIGAND MOTIFS OF HLA-C MOLECULES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, no. 24, 1 December 1993 (1993-12-01), pages 12005 - 12009, XP002068748, ISSN: 0027-8424 *
KIKUCHI AKIKO ET AL: "Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket.", IMMUNOGENETICS, vol. 43, no. 5, 1996, pages 268 - 276, XP002249196, ISSN: 0093-7711 *
KOZONO H ET AL: "PRODUCTION OF SOLUBLE MHC CLASS II PROTEINS WITH COVALENTLY BOUND SINGLE PEPTIDES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 369, no. 6476, 12 May 1994 (1994-05-12), pages 151 - 154, XP002018445, ISSN: 0028-0836 *
MUTIS TUNA ET AL: "Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.", NATURE MEDICINE., vol. 5, no. 7, July 1999 (1999-07-01), pages 839 - 842, XP002249195, ISSN: 1078-8956 *
REINSMOEN N L: "Cellular methods used to evaluate the immune response in transplantation.", TISSUE ANTIGENS, vol. 59, no. 4, August 2002 (2002-08-01), August, 2002, pages 241 - 250, XP002249198, ISSN: 0001-2815 *
UGER ET AL: "Creating CTL targets with epitope-linked beta 2-microglobulin constructs", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 4, 15 February 1998 (1998-02-15), pages 1598 - 1605, XP002115504, ISSN: 0022-1767 *
WHITE J ET AL: "Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, no. 5, 1999, pages 2671 - 2676, XP002959841, ISSN: 0022-1767 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Also Published As

Publication number Publication date
WO2003016905A2 (en) 2003-02-27
GB0120042D0 (en) 2001-10-10
AU2002319547A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
WO2003016905A3 (en) Determination of t-cell/mayor histocompatibility complex (mhc) reactivity
Sylvester‐Hvid et al. Establishment of a quantitative ELISA capable of determining peptide–MHC class I interaction
Nikas et al. Uterine pinopodes in peri-implantation human endometrium. Clinical relevance.
AU2002322241A1 (en) Rapid diagnostic device, assay and multifunctional buffer
WO2003102018A3 (en) Methods for quantitative proteome analysis of glycoproteins
Sadegh-Nasseri et al. Exogenous antigens bind MHC class II first, and are processed by cathepsins later
CA2055430A1 (en) Glycosylated Haemoglobin Assay
ATE433116T1 (en) IMMUNOASSAY TO DETERMINE THE RELEASE OF NEUROTENSIN INTO THE CIRCULATION
Appella et al. Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules.
DK0674766T3 (en) Method and apparatus for identifying a mycobacterial species responsible for a mycobacterial infection
ATE553846T1 (en) REAGENT CUVETTE
Long et al. Functional islet‐specific Treg can be generated from CD4+ CD25− T cells of healthy and type 1 diabetic subjects
Lei et al. Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines.
WO2005007677A3 (en) Affinity capture of peptides by microarray and related methods
DK0746767T3 (en) Analyzer cuvette, method and diagnostic test kit for determination of analytes in whole blood samples
WO2006031883A3 (en) Analysis of mhc-peptide binding interactions
Blum et al. Antigen-presenting cells and the selection of immunodominant epitopes.
WO2001090153A3 (en) Reagents for cell selection and methods of use
Mills et al. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity.
WO2008072275A3 (en) Telematic system for using diagnostic reagent strips and method for acquiring calibration data
de la Hoz Caballer et al. Chronic urticaria and Helicobacter pylori.
WO2005012509A3 (en) Method for immunotherapy of tumors
DK1386160T3 (en) Method for detecting blood cell antigens and antibodies directed against them
NO960149L (en) test Device
WO2004037160A3 (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP